In Vivo Study of Spherical Gold Nanoparticles: Inflammatory Effects and Distribution in Mice

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Chen, Hui ^a   Dorrigan, Alisha ^a   Saad, Sonia ^b   Hare, Dominic J ^a   Cortie, Michael B ^a   Valenzuela, Stella M ^a  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GOLD NANOPARTICLE; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL FAT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FAT MASS; GENE EXPRESSION; INFLAMMATION; LIVER; MACROPHAGE; MALE; MOUSE; NANOTOXICOLOGY; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION;

ADIPOSE TISSUE; ANIMALS; CYTOKINES; EATING; GENE EXPRESSION REGULATION; GOLD; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; MALE; METAL NANOPARTICLES; MICE; MICE, INBRED C57BL; ORGAN SIZE; RNA, MESSENGER; TISSUE DISTRIBUTION; TOXICITY TESTS, ACUTE;

EID: 84874577394     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058208     Document Type: Article

References (63)

1. Ujfalussy I, Koo E, Sesztak M, Gergely P, (2003) Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases. Z Rheumatol 62: 155-160.
2. Kean WF, Kean IRL, (2008) Clinical pharmacology of gold. Inflammopharmacology 16: 112-125.
3. Pissuwan D, Niidome T, Cortie MB, (2011) The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J Controlled Release 149: 65-71.
4. Pissuwan D, Cortie CH, Valenzuela SM, Cortie MB, (2010) Functionalised gold nanoparticles for controlling pathogenic bacteria. Trends Biotechnol 28: 207-213.
5. De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, et al. (2008) Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 29: 1912-1919.
6. Libutti SK, Paciotti GF, Byrnes AA, H. Richard Alexander J, Gannon WE, et al. (2010) Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 16: 6139-6149.
7. Cortie MB, (2004) The weird world of nanoscale gold. Gold Bulletin 37: 12-19.
8. Fischer HC, Chan WCW, (2007) Nanotoxicity: the growing need for in vivo study. Curr Opin Biotechnol 18: 565-571.
9. Chithrani BD, Ghazani AA, Chan WC, (2006) Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 6: 662-668.
10. Pissuwan D, Cortie CH, Valenzuela SM, Cortie MB, (2007) Gold nanosphere-antibody conjugates for hyperthermal therapeutic applications. Gold Bulletin 40: 121-129.
11. Pissuwan D, Valenzuela SM, Killingsworth MC, Xu XD, Cortie MB, (2007) Targeted destruction of murine macrophage cells with bioconjugated gold nanorods. Journal of Nanoparticle Research 9: 1109-1124.
12. Chithrani BD, Chan WC, (2007) Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 7: 1542-1550.
13. Tilg H, Moschen AR (2008) Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 14: 222 - 231.
14. Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, et al. (2010) Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest 120: 3466-3479.
15. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, et al. (2005) Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir 21: 10644-10654.
16. Khlebtsov N, Dykman L, (2011) Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev 40: 1647-1671.
17. Alkilany AM, Murphy CJ, (2010) Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J Nanopart Res 12: 2313-2333.
18. Shukla R, Bansal V, Chaudhary M, Bas A, Bhonde RR, et al. (2005) Biocompatibility of gold nanoparticles and their endocytotic fate Inside the cellular compartment: a microscopic overview. Langmuir 21: 10644-10654.
19. Pissuwan D, Cortie CH, Valenzuela SM, Cortie MB, (2007) Gold nanosphere-antibody conjugates for hyperthermal therapeutic applications. Gold Bulletin 40: 121-129.
20. Pissuwan D, Valenzuela SM, Killingsworth MC, Xu X, Cortie MB, (2007) Targeted destruction of murine macrophage cells with bioconjugated gold nanorods. J Nanopart Res 9: 1109-1124.
21. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD, (2005) Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 1: 325-327.
22. Lasagna-Reeves C, Gonzalez-Romero D, Barria MA, Olmedo I, Clos A, et al. (2010) Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem Biophys Res Comm 393: 649-655.
23. Sadauskas E, Danscher G, Stoltenberg M, Vogel U, Larsen A, et al. (2009) Protracted elimination of gold nanoparticles from mouse liver. Nanomedicine: Nanotechnology, Biology, and Medicine 5: 162-169.
24. Akhter S, Ahmad MZ, Ahmad FJ, Storm G, Kok RJ, (2012) Gold nanoparticles in theranostic oncology: current state-of-the-art. Expert Opin Drug Deliv 9: 1225-1243.
25. Pan Y, Neuss S, Leifert A, Fischler M, Wen F, et al. (2007) Size-dependent cytotoxicity of gold nanoparticles. Small 3: 1941-1949.
26. Zhang X-D, Wu H-Y, Wu D, Wang Y-Y, Chang J-H, et al. (2010) Toxicologic effects of gold nanoparticles in vivo by different administration routes. Int J Nanomedicine 5: 771-781.
27. Chen YS, Hung YC, Liau I, Huang GS, (2009) Assessment of the In Vivo Toxicity of Gold Nanoparticles. Nanoscale Res Lett 4: 858-864.
28. Balasubramanian SK, Jittiwat J, Manikandan J, Ong C-N, Yu LE, et al. (2010) Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. Biomaterials 31: 2034-2042.
29. Brown CL, Whitehouse MW, Tiekink ERT, Bushell GR, (2008) Colloidal metallic gold is not bio-inert. Inflammopharmacology 16: 133-137.
30. Mironava T, Hadjiargyrou M, Simon M, Jurukovsk V, Rafailovich MH, (2010) Gold nanoparticles cellular toxicity and recovery: Effect of size, concentration and exposure time. Nanotoxicology 4: 120-137.
31. Pernodet N, Fang X, Sun Y, Bakhtina A, Ramakrishnan A, et al. (2006) Adverse effects of citrate/gold nanoparticles on human dermal fibroblasts. Small 2: 766-773.
32. Arvizo RR, Rana S, Miranda OR, Bhattacharya R, Rotello VM, et al. (2011) Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine: Nanotechnology, Biology, and Medicine 7: 580-587.
33. Pompa PP, Vecchio G, Galeone A, Brunetti V, Sabella S, et al. (2011) In vivo toxicity assessment of gold nanoparticles in Drosophila. Nano Res 4: 405-413.
34. Johnston HJ, Hutchison G, Christensen FM, Peters S, Hankin S, et al. (2010) A review of the in vivo and in vitro toxicity of silver and gold particulates: Particle attributes and biological mechanisms responsible for the observed toxicity. Critical Reviews in Toxicology 40: 328-346.
35. Kang B, Mackey MA, El-Sayed MA, (2010) Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis. J Am Chem Soc 132: 1517-1519.
36. Dykman LA, Sumaroka MV, Staroverov SA, Zaitseva IS, Bogatyrev VA, (2004) Immunogenic properties of colloidal gold. Biology Bull 31: 75-79.
37. Lacerda SHDP, Park JJ, Meuse C, Pristinski D, Becker ML, et al. (2010) Interaction of gold nanoparticles with common human blood proteins. ACS Nano 4: 365.
38. Nimi N, Paul W, Sharma CP, (2011) Blood protein adsorption and compatibility studies of gold nanoparticles. Gold Bull 44: 15-20.
39. Yildirimer L, Thanh NTK, Loizidou M, Seifalian AM, (2011) Toxicological considerations of clinically applicable nanoparticles. Nano Today 6: 585-607.
40. Goel R, Shah N, Visaria R, Paciotti GF, Bischof JC, (2009) Biodistribution of TNF-alpha-coated gold nanoparticles in an in vivo model system. Nanomedicine (Lond) 4: 401-410.
41. Hare D, Reedy B, Grimm R, Wilkins S, Volitakis I, et al. (2009) Quantitative elemental bio-imaging of Mn, Fe, Cu and Zn in 6-hydroxydopamine induced Parkinsonism mouse models. Metallomics 1: 53-58.
42. Saad S, Agapiou DJ, Chen XM, Stevens V, Pollock CA, (2009) The role of Sgk-1 in the upregulation of transport proteins by PPAR-{gamma} agonists in human proximal tubule cells. Nephrol Dial Transplant 24: 1130-1141.
43. Edgar JA, Cortie MB (2009) Nanotechnological Applications of Gold. In: Corti C, Holliday R, editors. Gold Science and Applications. London: Taylor and Francis. 369-397.
44. Willette AA, Xu G, Johnson SC, Birdsill AC, Jonaitis EM, et al. (2012) Insulin Resistance, Brain Atrophy, and Cognitive Performance in Late Middle-Aged Adults. Diabetes Care.
45. Hotamisligil GS, (2006) Inflammation and metabolic disorders. Nature 444: 860-867.
46. Hotamisligil GS, Shargill NS, Spiegelman BM, (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259: 87-91.
47. Albanese A, Tang PS, Chan WC, (2012) The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14: 1-16.
48. Schenk S, Saberi M, Olefsky JM, (2008) Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 118: 2992-3002.
49. Deng ZJ, Liang M, Monteiro M, Toth I, Minchin RF, (2011) Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat Nanotechnol 6: 39-44.
50. Bastus NG, Sanchez-Tillo E, Pujals S, Farrera C, Kogan MJ, et al. (2009) Peptides conjugated to gold nanoparticles induce macrophage activation. Mol Immunol 46: 743-748.
51. Mascarenhas BR, Granda JL, Freyberg RH, (1972) Gold metabolism in patients with rheumatoid arthritis treated with gold compounds - reinvestigated. Arthritis Rheum 15: 391-402.
52. Gottlieb NL, Smith PM, Smith EM, (1972) Gold excretion correlated with clinical course during chrysotherapy in rheumatoid arthritis. Arthritis Rheum 15: 582-592.
53. Antonovych TT, (1981) Gold nephropathy. Ann Clin Lab Sci 11: 386-391.
54. Horton RJ (1983) Comparative safety and efficacy of auranofin and parenteral gold compounds: a review. Scand J Rheumatol Suppl 51: 100-110.
55. Champion GD, Graham GG, Ziegler JB, (1990) The gold complexes. Baillieres Clin Rheumatol 4: 491-534.
56. Clark P, Tugwell P, Bennett K, Bombardier C, (1989) Meta-analysis of injectable gold in rheumatoid arthritis. J Rheumatol 16: 442-447.
57. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, et al. (2007) Renal clearance of nanoparticles. Nat Biotechnol 25: 1165-1170.
58. Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, et al. (2004) Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 11: 169-183.
59. Cho WS, Cho M, Jeong J, Choi M, Cho HY, et al. (2009) Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicol Appl Pharmacol 236: 16-24.
60. Lanone S, Boczkowski J, (2006) Biomedical applications and potential health risks of nanomaterials: molecular mechanisms. Curr Mol Med 6: 651-663.
61. Walz DT, DiMartino MJ, Griswold DE, Intoccia AP, Flanagan TL, (1983) Biologic actions and pharmacokinetic studies of auranofin. Am J Med 75: 90-108.
62. Rossi J, Balthasar N, Olson D, Scott M, Berglund E, et al. (2011) Melanocortin-4 Receptors Expressed by Cholinergic Neurons Regulate Energy Balance and Glucose Homeostasis. Cell Metab 13: 195-204.
63. Thakor AS, Jokerst J, Zavaleta C, Massoud TF, Gambhir SS, (2011) Gold nanoparticles: a revival in precious metal administration to patients. Nano Lett 11: 4029-4036.